Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Supernus Pharmaceuticals, Inc. clinical trials
The registry lists 86 studies whose lead sponsor is Supernus Pharmaceuticals, Inc. or one of 4 companies grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 5, 2026.
Keep track of what changes. Save the Supernus Pharmaceuticals, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Supernus Pharmaceuticals, Inc..
- Supernus Pharmaceuticals, Inc.64 studiesSame company
Something wrong?
- Adamas Pharmaceuticals, Inc.10 studies →Acquired — became part of Supernus Pharmaceuticals, Inc., Nov 24, 2021 · source ↗
Something wrong?
- Sage Therapeutics6 studies →Acquired — became part of Supernus Pharmaceuticals, Inc., Jul 31, 2025 · source ↗
Something wrong?
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals3 studies →Acquired — became part of Supernus Pharmaceuticals, Inc., Jun 9, 2020 · source ↗
Something wrong?
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC3 studies →Acquired — became part of Supernus Pharmaceuticals, Inc., Jun 9, 2020 · source ↗
Something wrong?
Focus areas
Conditions Supernus Pharmaceuticals, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 86. Browse all 86 →
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDRecruitingNCT04781140Phase 4
- RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresRecruitingNCT06798896Phase 2
- Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyRecruitingNCT05518578Phase 2
- Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderRecruitingNCT07226661Phase 2
- Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:RecruitingNCT07219927
- SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresRecruitingNCT07141329Phase 2
- Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Active, not recruitingNCT02736656Phase 3
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb SpasticityTerminatedNCT04815967Phase 2/3
Sponsor listed in the registry: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC · First submitted after Solstice Neurosciences, LLC became part of Supernus Pharmaceuticals, Inc.
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb SpasticityTerminatedNCT04099667Phase 2/3
Sponsor listed in the registry: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC · First submitted before Solstice Neurosciences, LLC became part of Supernus Pharmaceuticals, Inc.
- Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood SymptomsCompletedNCT06185985Phase 4
- Therapy for Migraine Prevention in Children 6-11 Years of AgeTerminatedNCT04050293Phase 4
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseTerminatedNCT05655520Phase 3
- Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsCompletedNCT00626236Phase 2
- A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)CompletedNCT02942004Phase 3
- A Study With SAGE-547 for Super-Refractory Status EpilepticusCompletedNCT02477618Phase 3
- A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsCompletedNCT03770780Phase 1
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BCompletedNCT03787758Phase 1
- A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsCompletedNCT03771586Phase 1
- A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy SubjectsCompletedNCT03844906Phase 1
- Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy ParticipantsCompletedNCT05049343Phase 1
- Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionCompletedNCT02285504Phase 2
- Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum DepressionApproved for marketingNCT03924492
- A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)CompletedNCT05619692Phase 2
- Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status EpilepticusCompletedNCT02052739Phase 1/2
- A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)CompletedNCT03665038Phase 3
- A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)CompletedNCT02942017Phase 3
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)CompletedNCT04476017Phase 2
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)CompletedNCT04602624Phase 2
- An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status EpilepticusNo longer availableNCT02433314
- A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home SettingCompletedNCT05059600Phase 4
- An Open-Label Study Evaluating Brexanolone in Adults With TinnitusCompletedNCT05645432Phase 2
- A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionCompletedNCT02614547Phase 2
- A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)CompletedNCT05107128Phase 2
- 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseCompletedNCT05358821Phase 2
- A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentCompletedNCT05318937Phase 2
- A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential TremorTerminatedNCT05366751Phase 2/3
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- Infusion of Apomorphine: Long-term Safety StudyActive, not recruitingNCT02339064Phase 3
Sponsor listed in the registry: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals · First submitted before MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals became part of Supernus Pharmaceuticals, Inc.
- Study to Evaluate SAGE-324 in Participants With Essential TremorCompletedNCT05173012Phase 2
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHDTerminatedNCT03638466Phase 2
- Evaluation of Immediate-Release Viloxazine in Adults With ADHDCompletedNCT01107496Phase 1/2
- Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric SubjectsWithdrawnNCT05097079Phase 3
Sponsor listed in the registry: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC · First submitted after Solstice Neurosciences, LLC became part of Supernus Pharmaceuticals, Inc.
- Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating WomenCompletedNCT06259331Phase 4
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)TerminatedNCT02691182Phase 3
- Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHDCompletedNCT04786990Phase 4
- Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD TreatmentTerminatedNCT03597503Phase 3
- A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential TremorCompletedNCT04305275Phase 2
Sponsor listed in the registry: Sage Therapeutics · First submitted before Sage Therapeutics became part of Supernus Pharmaceuticals, Inc.
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)CompletedNCT02618434Phase 3
- Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDCompletedNCT04143217Phase 3
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)CompletedNCT02618408Phase 3
- Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®TerminatedNCT02549573Phase 4
Sponsor listed in the registry: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals · First submitted before MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals became part of Supernus Pharmaceuticals, Inc.